Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Avanos Medical (AVNS) Q2 Earnings and Revenues Top Estimates

Avanos Medical's (AVNS) second-quarter results benefit from contribution from Chronic Care segment.

Nevro (NVRO) Q2 Loss Narrower than Expected, Revenues Beat

Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.

Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag

Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates

DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.

Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss

Inogen (INGN) saw growth in revenues within its Rental segment in Q2.

The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services

The Zacks Analyst Blog Highlights: PulteGroup, Quidel, D.R. Horton and West Pharmaceutical Services

Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.

What Makes PerkinElmer (PKI) a Strong Momentum Stock: Buy Now?

Does PerkinElmer (PKI) have what it takes to be a top stock pick for momentum investors? Let's find out.

LabCorp (LH) Banks on Covance Amid Testing Volume Pressure

LabCorp's (LH) COVID-19 related research too has been progressing well.

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.

Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand

Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.

Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.

Nalak Das headshot

Wall Street is Northbound Defying All Concerns: 5 Top Picks

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract

Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.

DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss

DaVita's (DVA) dialysis services in the United States were solid in Q2.

NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates

NextGen (NXGN) benefited from its Recurring segment in Q1.

Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.